<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Anderson EMS Pocket Medic</title>
    <link rel="icon" href="../favicon.ico" type="image/png" />
    <link rel="stylesheet" href="../Environmental.css" />
    <link rel="stylesheet" href="OrgExposure.css" />
  </head>
  <body>
    <a href="../../../index.html" class="header-link">
      <div class="header">
        <h1>Anderson EMS Pocket Medic</h1>
      </div>
    </a>

    <div class="MainBody">
      <h2>Acetylcholinesterase Inhibitor Exposure<br>
        (Organophosphates / Nerve Agents)</h2>

      <div class="InitialBody">
        <table class="StartTable">
          <thead>
            <tr>
              <th>History</th>
              <th>Signs and Symptoms</th>
              <th>Differential</th>
            </tr>
          </thead>
          <tbody>
            <tr>
                <td>
                    • Substance<br><br>
                    • Time of ingestion or exposure<br><br>
                    • Route of exposure<br><br>
                    • Quantity of medication or toxin taken<br><br>
                    • Alcohol or other intoxicant taken<br><br>
                    • Past medical history<br><br>
                    • Medications<br><br>
                    • Decontamination performed<br><br>
                    • Treatment prior to arrival

                </td>
                <td>
                  <strong>DUMBELLS</strong><br><br>
                  • <strong><u>D</u></strong>efecation / <strong><u>D</u></strong>iarrhea<br><br>
                  • <strong><u>U</u></strong>rination; increase, loss of control<br><br>
                  • <strong><u>M</u></strong>iosis (pupils constrict)/Muscle
                  weakness/fasciculations<br><br>
                  • <strong><u>B</u></strong>ronchospasm, Bronchorrhea, 
                  Bradycardia (killer B’s)<br><br>
                  • <strong><u>E</u></strong>mesis<br><br>
                  • <strong><u>L</u></strong>acrimation<br><br>
                  • <strong><u>S</u></strong>alivation/Sweating

                </td>
                <td>
                  • Nerve agent exposure (e.g. VX, Sarin,
                  Soman, etc.)<br><br>
                  • Organophosphate exposure
                  (pesticide)<br><br>
                  • Vesicant exposure (e.g. Mustard Gas,
                  etc.)<br><br>
                  • Respiratory irritant exposure <br>(e.g.
                  Hydrogen Sulfide, Ammonia,
                  Chlorine, etc.)
                </td>
            </tr>
          </tbody>
        </table>
        <p>
          <span class="yellowCenter">Estimated Level of Exposure</span>
          <br><br>

              <img
                src="ExposureLevel.PNG"
                alt="Exposure Level Chart"
                style="
                display: block;
                margin-left: auto;
                margin-right: auto;
                max-width: 100%;
                height: auto;
                float: none;
                align-self: center;
                justify-self: center;
                "
            />
        </p>
        <h3 class="AllLevels">EMR & EMT</h3>
        <p>
          1. Assure scene is safe and the patient has been decontaminated if needed.<br><br>
          2. <a href="../../General/UniversalSources/Universal.html" class="working-link" title="Universal Patient Care SOG">UNIVERSAL PATIENT CARE</a>.<br><br>
          3. Save all bottles, containers or labels for information without exposing rescuers.<br><br>
          4. Relay information to incoming ambulance or call for intercept per 
          <a href="../../General/InterceptCriteriaSources/Intercept.html" class="working-link" title="Intercept Criteria SOG">INTERCEPT CRITERIA</a>.<br><br>
          5. Contact <strong>Resource Hospital Medical Control</strong> for any multiple victim response so that CHEMPACK activation
          may be initiated.<br><br>
          6. If available, administer via <a href="#" title="Coming Soon" class="placeholder-link">AUTOINJECTOR ATROPINE/PRALIDOXIME</a> (Ex. Duodote, Mark 1). Repeat
          every 3-5 minutes until symptoms of SLUDGE subside, most importantly secretions

        </p>
        <h3 class="PARAMEDIC">Paramedic/PHRN</h3>
        <p>
          1. Continue <strong>EMR / EMT TREATMENT</strong>.<br><br>
          2. If symptomatic, administer <a href="../../../DrugMaterial/AtropineFolder/Atropine.html" class="working-link" title="Atropine Med Page">ATROPINE</a>
          <strong>2 mg IV or IM</strong>.<br><br>
          3. Repeat <a href="../../../DrugMaterial/AtropineFolder/Atropine.html" class="working-link" title="Atropine Med Page">ATROPINE</a>
           <strong>2-4 mg IV</strong> every 3-5 minutes until symptoms of SLUDGE subside, most importantly
          secretions.<br><br>
          4. Establish IV access. Administer <strong>Isotonic IV Fluid</strong> to maintain SBP ≥ 90 mmHg or MAP ≥ 65 mmHg. Repeat
          fluid bolus as needed as long as lungs remain clear to maintain SBP ≥ 90 mmHg; maximum 2 liters.<br><br>
          5. Apply cardiac monitor.<br><br>
          6. If seizures occur, refer to 
          <a href="../../AdultMedical/SeizureSources/Seizure.html" class="working-link" title="Seizure SOG">SEIZURE / STATUS EPILEPTICUS</a> protocol.
        </p>
        <p>
          <strong>PEARLS</strong><br><br>
            • Continuous and ongoing patient reassessment is critical.<br><br>
            • Clinical response to treatment is demonstrated by the drying of secretion and the easing of respiratory
            effort.<br><br>
            • Initiation of and ongoing treatment should not be based upon heart rate or pupillary response.<br><br>
            • Atropine is the primary antidote for organophosphate, carbamate, or nerve agent exposures, and repeated
            doses should be administered liberally to patients who exhibit signs and symptoms of exposure or toxicity.<br><br>
            • Clinical effects of acetylcholinesterase inhibitor agents<br><br>
            <span class="Indention">
                a. The clinical effects are caused by the inhibition of the enzyme acetylcholinesterase which allows
                excess acetylcholine to accumulate in the nervous system.<br><br>
                b. The excess accumulated acetylcholine causes hyperactivity in muscles, glands, and nerves.
            </span><br>
            • Organophosphates (certain Insecticides)<br><br>
            <span class="Indention">
                a. Can be legally purchased by the general public.<br><br>
                b. Organophosphates (e.g. pesticides) penetrate tissues and bind to the patient’s body fat producing a
                prolonged period of illness and ongoing toxicity even during aggressive treatment.
            </span><br>
            • Nerve agents<br><br>
            <span class="Indention">
            a. Traditionally classified as weapons of mass destruction (WMD).<br><br>
            b. Not readily accessible to the general public.<br><br>
            c. Extremely toxic and rapidly fatal with any route of exposure.<br><br>
            d. GA (tabun), GB (sarin), GD (soman), GF, and VX are types of nerve agents and are WMDs.<br><br>
            e. Nerve agents can persist in the environment and remain chemically toxic for a prolonged period of
            time.<br>
            </span>
        </p>

        <table class="EndTable">
          <thead>
            <tr>
              <th><strong>KEY DOCUMENTATION ELEMENTS </strong></th>
              <th><strong>PERTINENT ASSESSMENT FINDINGS </strong></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>
                • Time to recognize initial signs and symptoms<br><br>
                • Number of repeated doses of atropine required
                for the secretions diminish and respirations to
                improve<br><br>
                • Patient reassessments<br><br>
                • Patient responses to therapeutic interventions<br><br>
                • Measures taken to decontaminate the patient<br><br>
                • Measures taken to protect clean environments
                from contamination

              </td>
              <td>
                • Signs and symptoms exhibited with the
                toxidromes of <strong>DUMBBELS</strong>
              </td>
            </tr>
          </tbody>
        </table>
        <table class="QMTable">
          <tr>
            <td><strong>QUALITY METRICS</strong><br /><br /></td>
          </tr>
          <tr>
            <td>
                • Recognition and appropriate treatment of patients

            </td>
          </tr>
        </table>
      </div>
    </div>
    <script src="https://code.jquery.com/jquery-3.7.1.min.js"></script>
    <script src="OrgExposure.js"></script>
  </body>
  <footer class="footer">
    <p>&copy; 2025 LukiWebSolutions. All rights reserved.</p>
  </footer>
</html>
 